Nordic Brain Tech Welcomes a Strong New Board

Nordic Brain Tech has appointed a new Board of Directors to support the company’s next phase of commercialization and international growth. With Cenli now launched and increasing interest from both customers and international stakeholders, the board has been strengthened with experienced leaders across consumer markets, pharma, operations, and scale-up expertise.

New Board Members

Christel Elise Kanli

Chair of the Board

Christel has experience from CFO and COO roles in growth companies such as Hofseth BioCare, Tunable, Smartfish and ScanWafer, combined with solid industrial and strategic background from multinationals. She was in Orkla for eight years doing M&A mainly in Asia, and has extensive international experience from around the globe. She is currently CFO in UBR Scandinavia.

Anders Guttormsen

Director

Anders is the CEO of Orkla Foods Norway, a leading branded consumer goods company with strong market positions across both the Norwegian grocery and out‑of‑home sectors in numerous categories. He has 19 years of experience at Orkla in a range of leadership roles and brings extensive expertise in strategy, sales, NRM, category management, negotiations, and market launches.

Anton Lorenz Bondesen

Director and investor

Anton is a founder and CEO of Stormast AS, an investment firm specializing in tech companies and health tech. Anton co-founded and successfully exited companies such as PasientSky and Convene. Stormast AS is an active investor in Nordic Brain Tech.

Lars Lundamo

Director

Lars is Procurement and Supply Chain Director at Dely AS, which is part of Jordanes that specializing in branded consumer industries. He has broad experience across logistics and value chains, as well as contract negotiations, from companies such as TINE and ASKO.

Renée Amundsen

Director

Renée has over 24 years of international experience in the pharmaceutical industry, including senior executive roles at Novo Nordisk and Merck KGaA. Most recently, she served as Corporate Vice President at Novo Nordisk with global responsibility for the diabetes portfolio, and has deep expertise in strategy, commercial execution and global scaling of innovative therapies.

With Cenli in the market, the board will actively support the management in scaling the product portfolio, developing strategic partnerships, and establishing efficient distribution models internationally.